[A25-41] Garadacimab (hereditary angioedema) – Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2025
Project no.:
A25-41
Commission:
Commission awarded on 03.03.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Indication:
For routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older
Result of dossier assessment:
Hint of considerable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-41